Barclays restated their buy rating on shares of Abbott Laboratories (NYSE:ABT) in a research note issued to investors on Monday morning. They currently have a $66.00 price objective on the healthcare product maker’s stock.

ABT has been the subject of a number of other research reports. Zacks Investment Research upgraded Abbott Laboratories from a hold rating to a buy rating and set a $58.00 target price for the company in a report on Friday, September 22nd. Jefferies Group reiterated a buy rating and set a $65.00 target price on shares of Abbott Laboratories in a report on Thursday, October 19th. JPMorgan Chase & Co. assumed coverage on Abbott Laboratories in a report on Friday, October 6th. They set a neutral rating and a $60.00 target price for the company. Morgan Stanley upgraded Abbott Laboratories from an equal weight rating to an overweight rating and set a $67.00 price target for the company in a report on Tuesday, January 2nd. Finally, Cowen restated a buy rating on shares of Abbott Laboratories in a report on Sunday, September 24th. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Abbott Laboratories presently has an average rating of Buy and an average target price of $60.24.

Shares of Abbott Laboratories (NYSE ABT) traded up $0.40 during trading hours on Monday, hitting $58.95. The stock had a trading volume of 4,240,900 shares, compared to its average volume of 6,166,962. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 1-year low of $39.25 and a 1-year high of $59.60. The stock has a market cap of $102,570.00, a PE ratio of 48.72, a P/E/G ratio of 1.88 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. During the same quarter in the previous year, the business earned $0.59 EPS. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. research analysts expect that Abbott Laboratories will post 2.5 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.90%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date is Thursday, January 11th. Abbott Laboratories’s dividend payout ratio is presently 87.60%.

In related news, insider Sharon J. Bracken sold 2,188 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $56.12, for a total transaction of $122,790.56. Following the sale, the insider now directly owns 25,618 shares of the company’s stock, valued at approximately $1,437,682.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Miles D. White sold 276,886 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the sale, the chairman now directly owns 3,677,913 shares in the company, valued at $200,115,246.33. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 501,172 shares of company stock worth $27,533,150. 0.76% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of ABT. Rowland & Co. Investment Counsel ADV acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $102,000. Heritage Trust Co raised its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares in the last quarter. Tributary Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter valued at approximately $106,000. Winfield Associates Inc. raised its position in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares in the last quarter. Finally, Thompson Davis & CO. Inc. increased its position in Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after buying an additional 370 shares during the period. 71.15% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Abbott Laboratories’ (ABT) “Buy” Rating Reaffirmed at Barclays” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/abbott-laboratories-abt-buy-rating-reaffirmed-at-barclays/1804447.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.